Choice of modelling technique for evaluating health care interventions
暂无分享,去创建一个
K Cooper | S C Brailsford | R Davies | S. Brailsford | R. Davies | K. Cooper | R. Davies
[1] Peter H. Millard,et al. A continuous time Markov model for the length of stay of elderly people in institutional long‐term care , 2005 .
[2] G. Bevan,et al. "Systematic" , 1966, Comput. J..
[3] R Davies,et al. Modelling patient flows and resource provision in health systems , 1994 .
[4] C. Bell,et al. The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.
[5] J R Beck,et al. Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] T. Jefferson,et al. Is vaccination against hepatitis B efficient? A review of world literature. , 1994, Health economics.
[7] I. U. Haq,et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment , 1999, Heart.
[8] Bhash Naidoo,et al. The Development of a Simulation Model of Primary Prevention Strategies for Coronary Heart Disease , 2002, Health care management science.
[9] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] P Tappenden,et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. , 2004, Health technology assessment.
[11] F A Sonnenberg,et al. Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.
[12] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[13] D. Owens,et al. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. , 2003, The American journal of medicine.
[14] A Briggs,et al. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.
[15] K Cooper,et al. Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction , 2005, Emergency Medicine Journal.
[16] R. G. Evans. Manufacturing Consensus, Marketing Truth: Guidelines for Economic Evaluation , 1995, Annals of Internal Medicine.
[17] Ruth Davies,et al. Using simulation modelling for evaluating screening services for diabetic retinopathy , 2000, J. Oper. Res. Soc..
[18] M C Weinstein,et al. Methodologic issues in policy modeling for cardiovascular disease. , 1989, Journal of the American College of Cardiology.
[19] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[20] Ruth Davies,et al. Simulating health systems: modelling problems and software solutions , 1995 .
[21] Ruth Davies,et al. The Development of a Simulation Model of the Treatment of Coronary Heart Disease , 2002, Health care management science.
[22] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[23] Sheldon Howard Jacobson,et al. Application of discrete-event simulation in health care clinics: A survey , 1999, J. Oper. Res. Soc..
[24] M. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[25] C. Lyles,et al. The view from managed care pharmacy. , 1996, Health affairs.
[26] M C Weinstein,et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[27] Milton C. Weinstein,et al. Recommendations for Reporting Cost-effectiveness Analyses , 1996 .
[28] Manouche Tavakoli,et al. Use of Quality Adjusted Life Years and Life Years Gained as Benchmarks in Economic Evaluations: A Critical Appraisal , 2004, Health care management science.
[29] R. Steingart,et al. Non-Q wave myocardial infarction: Identification of high and low risk subsets by clinical variables☆ , 1989 .
[30] N Melão,et al. Use of business process simulation: A survey of practitioners , 2003, J. Oper. Res. Soc..
[31] D. Zinner,et al. Are Methods for Estimating QALYs in Cost-Effectiveness Analyses Improving? , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[32] Ruth Davies,et al. The evaluation of disease prevention and treatment using simulation models , 2003, Eur. J. Oper. Res..
[33] B R Luce,et al. Health and economic outcomes modeling practices: a suggested framework. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] D. Feeny,et al. Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.
[35] Stirling Bryan,et al. Modelling in the economic evaluation of health care: selecting the appropriate approach , 2004, Journal of health services research & policy.
[36] W. R. Taylor,et al. Health Care CBA/CEA: An Update on the Growth and Composition of the Literature , 1993, Medical care.
[37] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[38] A Briggs,et al. Sensitivity analysis in economic evaluation: a review of published studies. , 1995, Health economics.
[39] Thomas C. Chalmers,et al. Economic Analysis in Randomized Control Trials , 1992, Medical care.
[40] A. Elixhauser,et al. Health care CBA and CEA from 1991 to 1996: an updated bibliography. , 1998, Medical care.
[41] J Karnon,et al. Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.
[42] G A Colditz,et al. Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.
[43] Jonathan Karnon,et al. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. , 2003, Health economics.
[44] M Sculpher,et al. Health Technology Assessment: Development and Future , 2009 .
[45] L. Goldman,et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. , 1987, American journal of public health.
[46] M C Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[47] Stewart Robinson,et al. Simulation: The Practice of Model Development and Use , 2004 .
[48] J. Mauskopf,et al. Prevalence-based economic evaluation. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[49] J. Seymour,et al. A TOOL TO IMPROVE QUALITY OF REPORTING PUBLISHED ECONOMIC ANALYSES , 2000, International Journal of Technology Assessment in Health Care.
[50] Lyn C. Thomas,et al. A portfolio of purchase contracts—an example of solving large-scale dynamic programming on parallel computers , 1995 .
[51] K Cooper,et al. A review of health care models for coronary heart disease interventions , 2006, Health care management science.
[52] T. Jefferson,et al. Quality of systematic reviews of economic evaluations in health care. , 2002, JAMA.